ADHD Research Today is a free monthly online journal that collates and summarizes the latest research about ADHD, including details on attention-deficit hyperactivity disorder, drugs, treatment, symptoms.

Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.

Barton J

North Staffordshire Combined Health Care NHS Trust, Moorlands Team, Abbey Hulton Clinic, Leek Road, Stoke-On-Trent, Staffordshire ST2 8BP, UK. Joanne.Barton@nsch-tr.wmids.nhs.uk

Atomoxetine is a novel, non-stimulant, highly selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention deficit/hyperactivity disorder (ADHD). Data from clinical trials show it to be well tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen not only in core symptoms of ADHD, but also in broader social and family functioning and self esteem. Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief. Atomoxetine does not appear to have abuse potential and is associated with a benign side effect profile. The development of atomoxetine thus represents an important advance in the pharmacological management of ADHD.

Published 24 January 2005 in Arch Dis Child, 90: i26-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 ADHD Research Today. All Rights Reserved.